SDIC Venture Capital

SDIC Venture Capital (国投创业) is a state-backed Chinese venture capital fund that shows up in elsewhere's corpus mainly through its healthcare and biotech deals. In the materials here it appears as a lead or participating investor in several 2023–2025 rounds: it co-led Inming Biotech's 700 million RMB Series A in 2023 alongside the China Venture Capital Fund , led Kelan Medicine's oversubscribed 100 million+ RMB A+ round in early 2025 , and joined Haichang Biotech's nearly 500 million RMB Series C in August 2025 — a syndicate the reporting framed as a "national capital strategic guidance + local industrial capital coordination" matrix . That pattern fits the broader picture 暗涌Waves has drawn of state-affiliated VC institutions focusing on hard-tech and research commercialization . Beyond these deal appearances, the corpus carries no profile of the fund itself — its founding date, AUM, or team are not covered.